ISB News

New York Times’ Matt Richtel on the ‘Elegant’ Immune System

In the first ISB-Town Hall Seattle Science Series of 2022, ISB President Dr. Jim Heath sat down with New York Times Pulitzer Prize winning reporter and bestselling author Matt Richtel for a wide ranging discussion that touched on the incredible immune system, distracted driving, social isolation, and much more. You can watch the hour-long fireside chat by clicking play on the video above. 

About the Science Series 

ISB and Town Hall Seattle have put on a number of virtual events focusing on a range of important scientific issues: The state of the microbiome field, the new science of longevity, why we age (and why we don’t have to), the importance of getting kids outside, STEM policy and advocacy, the politics of immunization, mining sewage to track population health, creating new senses for humans, and more. 

We will continue creating compelling events. To make sure you know of upcoming conversations, please follow us on Facebook, Twitter, LinkedIn and Instagram, and be sure to sign up for our newsletter for event updates.

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.